Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Randomized blinded trial of automated REBOA during CPR in a porcine model of cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Feasibility and safety of a fully percutaneous transcatheter aortic valve replacement program

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. 2020 ESC Guidelines for the management of adult congenital heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Philippe Garot
  • Xavier Iriart
  • Adel Aminian
  • Joelle Kefer
  • Xavier Freixa
  • Ignacio Cruz-Gonzalez
  • Sergio Berti
  • Liesbeth Rosseel
  • Reda Ibrahim
  • Kasper Korsholm
  • Jacob Odenstedt
  • Jens-Erik Nielsen-Kudsk
  • Jaqueline Saw
  • Lars Sondergaard
  • Ole De Backer
Vis graf over relationer

BACKGROUND: Optimal preprocedural planning is essential to ensure successful device closure of the left atrial appendage (LAA).

DESIGN: The PREDICT-LAA study is a prospective, international, multicentre, randomised controlled trial (ClinicalTrials.gov NCT04180605). Two hundred patients eligible for LAA closure with an Amplatzer Amulet device (Abbott, USA) will be enrolled in the study. Patients will be allocated to a computational simulation arm (experimental) or standard treatment arm (control) using a 1:1 randomisation. For patients randomised to the computational simulation arm, preprocedural planning will be based on the analysis of cardiac computed tomography (CCT)-based patient-specific computational simulations (FEops HEARTguide, Ghent, Belgium) in order to predict optimal device size and position. For patients in the control arm, preprocedural planning will be based on local practice including CCT analysis. The LAA closure procedure and postprocedural antithrombotic therapy will follow local practice in both arms. The primary endpoint of the study is incomplete LAA closure and device-related thrombus as assessed at 3 months postprocedural CCT. Secondary endpoints encompass procedural efficiency (number of devices used, number of repositioning, procedural time, radiation exposure, contrast dye), procedure-related complications within 7 days postprocedure and a composite of all-cause death and thromboembolic events at 12 months.

CONCLUSION: The objective of the PREDICT-LAA study is to test the hypothesis that a preprocedural planning for LAA closure with the Amplatzer Amulet device based on patient-specific computational simulations can result in a more efficient procedure, optimised procedural outcomes and better clinical outcomes as compared with a standard preprocedural planning.

TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04180605).

OriginalsprogEngelsk
TidsskriftOpen Heart
Vol/bind7
Udgave nummer2
ISSN2053-3624
DOI
StatusUdgivet - aug. 2020

Bibliografisk note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 62241278